• April 30, 2015
  • North America

NOVADAQ To Participate in May Investor Conferences

TORONTO – April 30, 2015  –  Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NASDAQ:NVDQ; TSX:NDQ), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced that management will participate in four investor conferences in May.

2015 Bloom Burton & Co. Healthcare Investor Conference: NOVADAQ is scheduled to present on May 4th at 11:00 am Eastern Time at the Sheraton Centre Toronto hotel in Toronto, ON.

Bank of America Merrill Lynch 2015 Health Care Conference: NOVADAQ is scheduled to present on Thursday, May 14th at 11:20 am Pacific Time at the Encore at the Wynn hotel in Las Vegas, NV.

2015 UBS Global Healthcare Conference: NOVADAQ is scheduled to present on May 19th at 3:00 pm Eastern Time at the Sheraton New York Times Square hotel in New York, NY.

12th Annual Craig-Hallum Institutional Investor Conference: NOVADAQ is scheduled to participate in a series of one-on-one meetings on May 27th at the Depot Renaissance Minneapolis hotel in Minneapolis, MN. There will be no formal presentation.

Live webcasts of the Bank of America Merrill Lynch 2015 Health Care Conference and the 2015 UBS Global Healthcare Conference presentations can be accessed on the company’s website at http://www.novadaq.com under the “Events” tab in the “Investors” section. Following the meetings, the presentations will be archived on the website for 90 days.

About Novadaq Technologies Inc.
Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 130 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.

SPY Imaging Systems are United States Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT, combines the capabilities of SPY Imaging with high definition (“HD”) visible light visualization offered by conventional endoscopes. LUNA is used to assess perfusion in patients being treated for non-healing wounds. In December 2014, NOVADAQ and LifeNet Health jointly announced the signing of a multi-year agreement appointing NOVADAQ the exclusive worldwide distributor of LifeNet Health’s DermACELL acellular tissue products for wound and breast reconstruction surgery.

Forward-Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on NOVADAQ’s current beliefs as well as assumptions made by and information currently available to NOVADAQ and relate to, among other things, the Company’s strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by NOVADAQ in its public securities filings available at www.sec.gov and www.sedar.com, actual events may differ materially from current expectations. NOVADAQ disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

NOVADAQ, SPY, PINPOINT and LUNA are registered trademarks of Novadaq Technologies Inc. DermACELL is a registered trademark of LifeNet Health.

Stephen Kilmer
Investor Relations